Trogenix Appoints Global Experts, Prof. Nada Jabado And Prof. Burkhard Becher, To Its Scientific Advisory Board For Strategic Growth

Trogenix Ltd, an innovative biotech company focused on developing cutting-edge cancer therapies, has announced the immediate appointment of Prof. Nada Jabado and Prof. Burkhard Becher to its Scientific Advisory Board (SAB). These distinguished experts will enhance the company's scientific capabilities in developing targeted cancer treatments, with Prof. Jabado contributing her expertise in pediatric neuro-oncology and Prof. Becher providing insights into immunotherapy. They join Trogenix’s existing team of world-leading SAB members, who specialize in gene regulation, gene delivery, immunotherapy, neurosurgery, oncology, and regenerative medicine.

Prof. Nada Jabado is a Professor of Paediatrics at McGill University and a paediatric haematologist-oncologist at the Montreal Children’s Hospital. Her pioneering research has revolutionized the understanding of pediatric gliomas by identifying histone mutations as key drivers of these cancers. She began her career as an independent investigator at the Research Institute of the McGill University Health Centre, where she established an unparalleled research program in pediatric brain tumors. 

Prof. Jabado is an Officer of the Order of Canada, a CIHR Tier 1 Canada Research Chair in Paediatric Oncology, and a Fellow of the Royal Society of Canada. She is also a member of the Canadian Academy of Health Sciences and has served on the CIHR Governing Council. Prof. Jabado holds a PhD in Immunology from the Marie Curie Institute and completed a postdoctoral fellowship in Biochemistry at McGill University.

Prof. Burkhard Becher is the Professor and Chair of the Institute of Experimental Immunology at the University of Zurich. With over 270 publications, Prof. Becher has made significant contributions to the understanding of cytokine-mediated communication networks in immune cell function, particularly in inflammation and cancer immunotherapy. His research has led to groundbreaking insights into the role of myeloid cells, lymphocytes, and cytokines like GM-CSF, IL-12, and IL-23. 

Steve Pollard, Chief Scientific Officer at Trogenix, mentioned, “We are honoured to welcome Nada Jabado and Burkhard Becher to our Scientific Advisory Board. Both are globally recognised leaders whose pioneering work in paediatric oncology and neuroimmunology, respectively, aligns perfectly with Trogenix’s mission to transform treatment paradigms for aggressive cancers. Their insights will further elevate our already world-class SAB and each will provide invaluable guidance across our programmes and help guide future applications for our Odysseus platform.”

Prof. Becher has received numerous accolades, including being named a Highly Cited Researcher by Clarivate Analytics since 2018 and receiving the prestigious ERC Advanced Grant in 2019. He holds a PhD from the University of Cologne and conducted his graduate research in neuroimmunology at McGill University, followed by a postdoctoral fellowship at Dartmouth Medical School.